High doses of deferiprone may be associated with cerebellar syndrome.
Beau-Salinas
F
F
Bretonneau Hospital, CHRU of Tours, Regional Centre of Pharmacovigilance, Department of Pharmacology, 37044 Tours Cedex 9, France. f.beau-salinas@chu-tours.fr
Guitteny
M A
MA
Donadieu
J
J
Jonville-Bera
A P
AP
Autret-Leca
E
E
D002526:Cerebellar Diseases / Q000139:chemically induced*; D002648:Child; D000077543:Deferiprone; D005260:Female; D006801:Humans; D007502:Iron Chelating Agents / Q000008:administration & dosage / Q000009:adverse effects*; D019190:Iron Overload / Q000188:drug therapy*; D008297:Male; D011728:Pyridones / Q000008:administration & dosage / Q000009:adverse effects*; D017086:beta-Thalassemia / Q000188:drug therapy
D007502:Iron Chelating Agents; D011728:Pyridones; D000077543:Deferiprone